Disease relevance of Chilblains

• Infliximab induced chilblain lupus in a patient with rheumatoid arthritis [1].
• Thymoxamine for Raynaud's disease and chilblains [2].

High impact information on Chilblains

• Chilblains following a chronic course may reveal connective tissue disease, and patients affected with chilblains associated with autoimmune abnormalities may develop severe SLE [3].
• The treatment of chilblains with nifedipine: the results of a pilot study, a double-blind placebo-controlled randomized study and a long-term open trial [4].
• Chronic facial discoid LE usually appears before the chilblain form but, in most instances, resolves even though the chilblain lesions persists [5].
• The chilblain lesions are the result of microvascular injury secondary to exposure to cold and possibly hyperviscosity from immunological abnormalities, Elevated serum gammaglobulins, positive latex factor and speckled pattern antinuclear factor are common [5].
• In conclusion, the present study suggests that chilblain LE is associated with SSA/Ro autoantibodies, as is SCLE, hypergammaglobulinemic purpura and neonatal lupus erythematosus [6].

Chemical compound and disease context of Chilblains

• At a dose of 20 mg to 60 mg daily, nifedipine significantly reduced the time to clearance of existing lesions and prevented the development of new chilblains [4].

Gene context of Chilblains

• Recently, necrotic livedo of the extremities, severe chilblains and severe frostbite have been observed in protein C or S deficient patients [7].

References